DMAC.US DiaMedica Therapeutics Inc

Healthcare Biotechnology USA Stocks
8.79 USD
Close of Nov 13, 2026
5.25 11.00
Market cap
USD 474M
P/E
-
P/B
13.14x
ROE
-146.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DMAC.US undervalued?

Graham number

The Graham number of DiaMedica Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

DiaMedica Therapeutics Inc fundamental analysis

No fundamental analysis for DiaMedica Therapeutics Inc yet.

DiaMedica Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a r…

Full company profile